S-19 Frontier of molecular therapy for lysosomal diseases utilizing recombinant gene technology   S19-1. Elucidation of molecular pathogenesis of lysosomal diseases - for development of therapy   S19-2. Current enzyme replacement therapies for LSDs and the potential for CNS treatment   S19-3. Engineering of M6P-type glycan in yeast to produce a potential enzyme for replacement therapy of lysosomal diseases   S19-4. Current progress of gene therapy for single gene disorders   S19-5. Development of the coming generation enzyme replacement therapy for lysosomal diseases